Loading...
Loading...
India accounts for a significant share of global Cyclophosphamide exports, with 259+ registered manufacturers shipping to buyers across 114+ countries — yet a handful of companies dominate the shipments. CIPLA LIMITED holds the largest share at 42.1% (export value: $8.2M). Close behind, EUGIA PHARMA SPECIALITIES LIMITED (27.3%, $5.3M). ALEMBIC PHARMACEUTICALS LIMITED (4.3%, $830.4K). The Sankey diagram below maps every supplier's customer flow in detail. All figures are drawn from Indian Customs (DGFT) shipping bill records.
Comprehensive supplier network intelligence dashboard
Flow of Cyclophosphamide from leading Indian exporters to their key global customers
Top Suppliers → Customer Networks
The Cyclophosphamide export market from India is led by CIPLA LIMITED, which alone commands a 42.1% share, shipping $8.2M worth of product across 11 shipments. The second-largest exporter, EUGIA PHARMA SPECIALITIES LIMITED, contributes $5.3M (27.3%) to the overall market. Combined, the top two suppliers alone account for 69.4% of all Cyclophosphamide exports, indicating a relatively concentrated supply base.
Across all 259 tracked manufacturers, the total Cyclophosphamide export value stands at $19.5M from 2.1K shipments. The market average shipment value is $9.2K. The single largest buyer relationship in terms of trade value is CIPLA USA INC UPS SUPPLY CHAIN SOLU, receiving $8.1M worth of product.
The combined buyer network spans 13 named purchasing companies, including CIPLA USA INC UPS SUPPLY CHAIN SOLU, EUGIA US LLC, J. KNIPPER & COMPANY,, COMMERCIAL BANK, P P & C P L and 8 others. These buyers represent pharmaceutical manufacturers, distributors, hospital procurement groups, and generic drug producers operating across multiple continents.
CIPLA LIMITED is the first-largest Cyclophosphamide exporter from India, with a market share of 42.1% and a total export value of $8.2M across 11 shipments. Their average shipment value of $744.4K is above the market average of $9.2K, suggesting premium or bulk contract pricing.
CIPLA LIMITED serves 2 named buyers in our database. CIPLA USA INC UPS SUPPLY CHAIN SOLU is the dominant customer, accounting for 99.0% of this supplier's tracked business. Top customers include:
• CIPLA USA INC UPS SUPPLY CHAIN SOLU — $8.1M across 11 shipments (99.0% of this supplier's total exports)
• CIPLA USA INC UPS SUPPLY CHAIN SOLU — $78.0K across 0 shipments (1.0% of this supplier's total exports)
Key Insight: CIPLA LIMITED's per-shipment value of $744.4K is 7987% above the market average of $9.2K, consistent with large-order contracts or value-added formulations.
EUGIA PHARMA SPECIALITIES LIMITED is the second-largest Cyclophosphamide exporter from India, with a market share of 27.3% and a total export value of $5.3M across 22 shipments. Their average shipment value of $241.3K is above the market average of $9.2K, suggesting premium or bulk contract pricing.
EUGIA PHARMA SPECIALITIES LIMITED serves in our database. Top customers include:
Once Cyclophosphamide leaves the manufacturing plants of companies like CIPLA LIMITED and EUGIA PHARMA SPECIALITIES LIMITED, it travels to 5 destination markets with a combined import value of $19.5M. United States absorbs the largest share at 83.8% ($16.3M), followed by Ethiopia (2.3%) and Peru (1.4%).
In United States — the top destination — named importers include CIPLA USA INC UPS SUPPLY CHAIN SOLU, EUGIA US LLC, EUGIA US LLC,. In Ethiopia, key buyers are COMMERCIAL BANK.
This geographic spread reflects Cyclophosphamide's role as an essential active pharmaceutical ingredient (API) and finished dosage form — sourced primarily from India due to its cost-competitive, WHO-compliant manufacturing base. The Sankey diagram below maps these destination countries to their named importers in detail.
Comprehensive geographic market intelligence dashboard
Trade flow of Cyclophosphamide exports from India — top destination countries and the named companies importing it
Top Countries → Global Importers
United States ranks as the first-largest destination for Cyclophosphamide imports from India, with a total trade value of $16.3M across 61 shipments — representing a 83.8% share of all Cyclophosphamide exports. The average shipment value of $267.2K is above the global average of $9.2K, indicating high-value procurement contracts or branded formulations. This market is served by 8 tracked buyers.
Named Cyclophosphamide importers in United States: CIPLA USA INC UPS SUPPLY CHAIN SOLU is the largest buyer, accounting for 50.7% ($8.3M) of this market's total imports.
• CIPLA USA INC UPS SUPPLY CHAIN SOLU — $8.3M (50.7% of United States's total)
• EUGIA US LLC — $3.4M (21.1% of United States's total)
• EUGIA US LLC, — $1.9M (11.5% of United States's total)
Key Insight: United States's per-shipment average of $267.2K (2803% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
United States is a key market for Cyclophosphamide imports from India.
Visual overview of India's cyclophosphamide supply chain network — top suppliers, destinations, pricing, and trade routes
This video covers India's cyclophosphamide pharmaceutical supply chain network — $19.5M in total trade, 114 verified manufacturers. Data sourced from Indian Customs (DGFT) shipment records.
Latest developments and market context
Detailed market intelligence for Cyclophosphamide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
• EUGIA US LLC — $3.4M across 14 shipments (64.7% of this supplier's total exports)
• EUGIA US LLC — $1.9M across 8 shipments (35.3% of this supplier's total exports)
Key Insight: EUGIA PHARMA SPECIALITIES LIMITED's per-shipment value of $241.3K is 2521% above the market average of $9.2K, consistent with large-order contracts or value-added formulations.
ALEMBIC PHARMACEUTICALS LIMITED is the third-largest Cyclophosphamide exporter from India, with a market share of 4.3% and a total export value of $830.4K across 30 shipments. Their average shipment value of $27.7K is above the market average of $9.2K, suggesting premium or bulk contract pricing.
ALEMBIC PHARMACEUTICALS LIMITED serves 4 named buyers in our database. J. KNIPPER & COMPANY, is the dominant customer, accounting for 56.3% of this supplier's tracked business. Top customers include:
• J. KNIPPER & COMPANY, — $467.5K across 17 shipments (56.3% of this supplier's total exports)
• J. KNIPPER & COMPANY, — $152.4K across 6 shipments (18.4% of this supplier's total exports)
• J. KNIPPER & COMPANY, — $147.1K across 5 shipments (17.7% of this supplier's total exports)
• J. KNIPPER & COMPANY, — $63.4K across 2 shipments (7.6% of this supplier's total exports)
Key Insight: ALEMBIC PHARMACEUTICALS LIMITED's per-shipment value of $27.7K is 201% above the market average of $9.2K, consistent with large-order contracts or value-added formulations.
VENUS REMEDIES LIMITED is the fourth-largest Cyclophosphamide exporter from India, with a market share of 2.4% and a total export value of $474.8K across 13 shipments. Their average shipment value of $36.5K is above the market average of $9.2K, suggesting premium or bulk contract pricing.
VENUS REMEDIES LIMITED serves 4 named buyers in our database. COMMERCIAL BANK is the dominant customer, accounting for 92.4% of this supplier's tracked business. Top customers include:
• COMMERCIAL BANK — $438.9K across 12 shipments (92.4% of this supplier's total exports)
• P P & C P L — $19.1K across 1 shipments (4.0% of this supplier's total exports)
• K P L — $16.8K across 0 shipments (3.5% of this supplier's total exports)
• 2MG I — $1 across 0 shipments (0.0% of this supplier's total exports)
Key Insight: VENUS REMEDIES LIMITED's per-shipment value of $36.5K is 297% above the market average of $9.2K, consistent with large-order contracts or value-added formulations.
SP ACCURE LABS PRIVATE LIMITED is the fifth-largest Cyclophosphamide exporter from India, with a market share of 1.4% and a total export value of $262.9K across 22 shipments. Their average shipment value of $12.0K is above the market average of $9.2K, suggesting premium or bulk contract pricing.
SP ACCURE LABS PRIVATE LIMITED serves 5 named buyers in our database. HIRAD PHARMED UNIT is the dominant customer, accounting for 69.2% of this supplier's tracked business. Top customers include:
• HIRAD PHARMED UNIT — $181.9K across 15 shipments (69.2% of this supplier's total exports)
• COMERCIALIZADORA ALE — $48.0K across 4 shipments (18.3% of this supplier's total exports)
• CENTRO NACIONAL DE A — $17.1K across 1 shipments (6.5% of this supplier's total exports)
• LS MEDISURE PERU SAC — $10.0K across 1 shipments (3.8% of this supplier's total exports)
• Pharma Associates — $5.8K across 0 shipments (2.2% of this supplier's total exports)
Key Insight: SP ACCURE LABS PRIVATE LIMITED's per-shipment value of $12.0K is 30% above the market average of $9.2K, consistent with large-order contracts or value-added formulations.
GETWELL PHARMACEUTICALS is the fifth-largest Cyclophosphamide exporter from India, with a market share of 1.3% and a total export value of $244.3K across 94 shipments. Their average shipment value of $2.6K is below the market average of $9.2K, reflecting a high-volume, competitive pricing strategy.
GETWELL PHARMACEUTICALS serves 1 named buyer in our database. DR REDDYS LABORATORI is the dominant customer, accounting for 100.0% of this supplier's tracked business. Top customers include:
• DR REDDYS LABORATORI — $244.3K across 94 shipments (100.0% of this supplier's total exports)
Key Insight: GETWELL PHARMACEUTICALS operates with high shipment frequency (94 shipments) at a per-shipment value of $2.6K, indicating a broad distribution network with many smaller, regular orders.
Ethiopia ranks as the second-largest destination for Cyclophosphamide imports from India, with a total trade value of $445.0K across 5 shipments — representing a 2.3% share of all Cyclophosphamide exports. The average shipment value of $89.0K is above the global average of $9.2K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Cyclophosphamide importers in Ethiopia: COMMERCIAL BANK is the largest buyer, accounting for 98.6% ($438.9K) of this market's total imports.
• COMMERCIAL BANK — $438.9K (98.6% of Ethiopia's total)
Key Insight: Ethiopia's per-shipment average of $89.0K (867% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Ethiopia is a key market for Cyclophosphamide imports from India.
Peru ranks as the third-largest destination for Cyclophosphamide imports from India, with a total trade value of $279.4K across 6 shipments — representing a 1.4% share of all Cyclophosphamide exports. The average shipment value of $46.6K is above the global average of $9.2K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Cyclophosphamide importers in Peru: DS PHARMA PERU S.A.C. is the largest buyer, accounting for 42.9% ($119.9K) of this market's total imports.
• DS PHARMA PERU S.A.C. — $119.9K (42.9% of Peru's total)
Key Insight: Peru's per-shipment average of $46.6K (406% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Peru is a key market for Cyclophosphamide imports from India.
Philippines ranks as the fourth-largest destination for Cyclophosphamide imports from India, with a total trade value of $277.3K across 55 shipments — representing a 1.4% share of all Cyclophosphamide exports. The average shipment value of $5.0K is below the global average of $9.2K, consistent with generic/API volume purchasing. This market is served by 1 tracked buyer.
Named Cyclophosphamide importers in Philippines: AMBICA INTERNATIONAL CORPORATION is the largest buyer, accounting for 97.0% ($269.0K) of this market's total imports.
• AMBICA INTERNATIONAL CORPORATION — $269.0K (97.0% of Philippines's total)
Key Insight: Philippines receives frequent, smaller shipments of Cyclophosphamide — typical of markets with distributed retail pharmacy or hospital networks sourcing generics at volume.
Philippines is a key market for Cyclophosphamide imports from India.
Mexico ranks as the fifth-largest destination for Cyclophosphamide imports from India, with a total trade value of $256.5K across 19 shipments — representing a 1.3% share of all Cyclophosphamide exports. The average shipment value of $13.5K is above the global average of $9.2K, indicating high-value procurement contracts or branded formulations. This market is served by 1 tracked buyer.
Named Cyclophosphamide importers in Mexico: CALLEX MEDICAMENTOS S. DE RL DE CV is the largest buyer, accounting for 34.3% ($88.1K) of this market's total imports.
• CALLEX MEDICAMENTOS S. DE RL DE CV — $88.1K (34.3% of Mexico's total)
Key Insight: Mexico's per-shipment average of $13.5K (47% above global average) points to a market favouring large-batch or high-value pharmaceutical procurement.
Mexico is a key market for Cyclophosphamide imports from India.
Top supplier: 2 customers
6 suppliers → 114 countries
Network value: $19.5M
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,113 Verified Shipments
259 manufacturers in network
Expert-Reviewed
By pharmaceutical trade specialists